Phase 3Recruiting

Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.

A Multicentric, Randomized, Double Blind, Double Dummy, Prospective, Parallel Group, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules Versus FDC of Pregabalin plus Methylcobalamin plus Nortriptyline Tablets in Subjects with Diabetic Peripheral Neuropathic Pain Coexisting with Vitamin B12 Deficiency. - NIL

Sponsor
Ravenbhel Healthcare Pvt. Ltd. (Industry)
Enrollment
210 planned
Conditions
Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications
Interventions
FDC of Pregabalin 75 mg plus Methylcobalamin 1500 mcg plus Duloxetine DR 20 mg Capsule and Matching Placebo Tablet
Registry
CTRI-2024-01-062147

Full record on the Clinical Trials Registry – IndiaSource: WHO ICTRP, processed April 29, 2024

Primary outcomes

  • Mean change in visual analog scale (VAS) from baseline to end of the treatment. (12 weeks)Timepoint: 12 weeks

History

  1. Last registry update

  2. Started

  3. Registered